

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA MEDICAL SYSTEM HOLDINGS LIMITED**

**康哲藥業控股有限公司\***

*(Incorporated in the Cayman Islands with Limited Liability)*

**(Stock Code: 867)**

### **Voluntary and Business Update Announcement New Drug Application of Diazepam Nasal Spray Accepted in China**

China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 05 July 2021, New Drug Application of Diazepam Nasal Spray (the “Product”) has been accepted by the National Medical Products Administration of the People’s Republic of China. The Product is an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in people with epilepsy 6 years of age and older. The Product had been approved by the U.S. Food and Drug Administration.

The announcement is made on a voluntary basis by the Company. Shareholders and investors are advised to exercise caution in dealing in the shares and other securities of the Company.

By order of the Board  
China Medical System Holdings Limited  
**Lam Kong**  
*Chairman*

Hong Kong, 05 July 2021

*As at the date of the announcement, the directors of the Company comprise (i) Mr. Lam Kong, Mr. Chen Hongbing and Ms. Chen Yanling as executive Directors; and (ii) Mr. Wu Chi Keung, Mr. Leung Chong Shun and Ms. Luo, Laura Ying as independent non-executive Directors.*